Debiopharm at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Debiopharm brings 2 presentations to IDWeek 2026 in Washington. Its program centres on afabicin for bone and joint infections caused by Staphylococcus species. One study reports clinical and microbiological response in a clinical trial, and another asks whether the drug spares the gut microbiome, using stool microbiome and metabolomics analysis.
| Organization | IDWeek 2026 Attendance |
|---|---|
Debiopharm Lausanne, Switzerland | |
Swiss biopharmaceutical company developing afabicin, an antibiotic that targets staphylococci. | Poster Sat Oct 24 12:15pm–1:30pm Clinical and Microbiological Response to Afabicin in a Phase 2 Clinical Trial in Patients with Bone and Joint Infections Caused by Staphylococcus spp. Poster Sat Oct 24 12:15pm–1:30pm Microbiota-Sparing Potential of Afabicin: Microbiome and Metabolomics Analysis of Stool Samples From Patients with BJI Treated with Afabicin for up to 6 Weeks |
Instantly find 20 buyers from Debiopharm
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction